Fluorinov Pharma (acquired by Trillium Therapeutics)

facit.ca
Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Exit
Fund:
Compass Rose
Breakthrough medicinal chemistry technology enabling fluorine atoms linked to drug candidates to improve therapeutic potency, stability and safety. The lead candidate, FV162, is an oral proteasome inhibitor for the treatment of blood cancers.

Related news

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.